Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

12-O-Tetradecanoylphorbol-13-acetate (TPA) is anti-tumorigenic in liver cancer cells via inhibiting YAP through AMOT.

Scientific reports - 21 Mar 2017

Zhu Guoqing, Chen Yan, Zhang Xiao, Wu Qi, Zhao Yinghui, Chen Yuxin, Sun Fenyong, Qiao Yongxia, Wang Jiayi

Abstract excerpt

TPA stimulates carcinogenesis in various types of cancers. However, we found that TPA inhibits transformative phenotypes in liver cancer cells via the translocation of YAP from the nucleus, where it functions as a transcriptional co-factor, to the cytoplasm. Such effects led to a separation of YAP from its dependent transcription factors. The inhibitory effects of TPA on YAP were AMOT dependent. Without AMOT, TPA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspase 3
Share to Caspase 7

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Transformation, Neoplastic

Share to Heterografts

Share to Intercellular Signaling Peptides and Proteins

Share to Liver Neoplasms

Share to Microfilament Proteins

Share to Tetradecanoylphorbol Acetate

Source

Open in PubMed Open full text

Identifiers

PMID: 28322318
DOI: 10.1038/srep44940
PMCID: PMC5359578

Genes

AMOT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

12-O-Tetradecanoylphorbol-13-acetate (TPA) is anti-tumorigenic in liver cancer cells via inhibiting YAP through AMOT.PMID 28322318Read ↗

The biology of YAP in programmed cell deathSemantic proximity Read ↗

Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinomaSemantic proximity Read ↗

The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors.Semantic proximity Read ↗

Targeting YAP and Hippo signaling pathway in liver cancerSemantic proximity Read ↗

Emerging role of Hpo signaling and YAP in hepatocellular carcinomaSemantic proximity Read ↗

The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human diseaseSemantic proximity Read ↗

TFCP2 Is Required for YAP-Dependent Transcription to Stimulate Liver Malignancy.Semantic proximity Read ↗

Tristetraprolin Promotes Hepatic Inflammation and Tumor Initiation but Restrains Cancer Progression to MalignancySemantic proximity Read ↗

YAP activates the Hippo pathway in a negative feedback loop.Semantic proximity Read ↗

Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cellsSemantic proximity Read ↗

Yap suppresses T cell function and infiltration in the tumor microenvironmentSemantic proximity Read ↗

The polyomavirus middle T-antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.